Drug Discovery Featured Articles & Applications

  1. Weight Of Evidence Assessments For Carcinogenicity Studies: An Overview 8/20/2025

    Carcinogenicity assessments often rely heavily on two-year rodent bioassays. The weight of evidence (WoE) approach seeks to streamline this process, combining thorough science with regulatory practicality.

  2. Advancing CAR T Cell Therapy with Logic Gate Engineering 8/19/2025

    Logic gating applies Boolean logic principles to CAR T cell design to improve precision and minimize collateral damage.

  3. Oligos Step Into The Spotlight: A Growing Force In Genetic Medicine 8/18/2025

    Oligonucleotide therapeutics are experiencing a new wave of momentum. As the science evolves and the market opportunity expands, the landscape is poised for continued growth and diversification.

  4. From Concept To Confidence: A Collaborative Path To Validating NAMs 8/15/2025

    On August 1, 2025, the Foundation for the National Institutes of Health (FNIH) released a Request for Information (RFI) inviting proposals for pilot projects to accelerate the development, validation, and regulatory acceptance of New Approach Methodologies (NAMs). For drug developers, participating in this process offers not only scientific collaboration but also the potential to co-develop regulatory-grade NAMs aligned with FDA and NIH priorities.

  5. How CZ Biohub's AI Agents Might Assist Drug Developers Beyond R&D 8/15/2025

    Researchers at Stanford and the Chan Zuckerberg Biohub San Francisco developed an open-source platform of virtual researchers who talk to each other.

  6. Heart-In-A-Jar Organ Model Earns Regulatory Respect After 25 Years In The Making 8/7/2025

    Aligned with new FDA support for new approach methodologies (NAMs), Ronald Li, Ph.D, and Kevin Costa, Ph.D., share their story of creating Novoheart's mini heart organ model and discuss its current use in clinical trials.

  7. Developing Small Molecule Therapeutics To Tackle Heart Failure In DMD Patients 8/6/2025

    A great deal of attention has been focused on development of genetic therapies to treat DMD. But Revidia Therapeutics is focusing on developing small molecule drugs.

  8. The Rise Of NAMs 7/31/2025

    New Approach Methods (NAMs) are rapidly being accepted as replacements for preclinical animal tests long considered to be the gold standard. NAMs include systems of organoids, organs-on-chips, AI-based prediction models, and non-mammalian species.

  9. AI Data Security: The 83% Compliance Gap Facing Pharmaceutical Companies 7/23/2025

    A new study reveals a shocking truth: only 17% of pharmaceutical companies — including many CDMOs — have implemented automated controls to prevent sensitive data from leaking through AI tools.

  10. Breaking Down Silos: How ERP Platforms Are Accelerating Drug Discovery And Early-Stage Development 7/23/2025

    Modern enterprise resource planning (ERP) systems, particularly those built with pharma in mind, can be tailored specifically to support research workflows just as effectively as they manage commercial operations.